» Articles » PMID: 15908967

High-dose Corticosteroid Therapy for Bronchiolitis Obliterans After Bone Marrow Transplantation in Children

Overview
Specialty General Surgery
Date 2005 May 24
PMID 15908967
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Bronchiolitis obliterans (BO) is a rare but serious complication of paediatric allogenic bone marrow transplantation (BMT). Currently, there is no clear evidence that therapeutic interventions have a positive impact on the course of the disease. We here report our experience with high-dose pulse methylprednisolone therapy in children after BMT. Nine patients fulfilling clinical and radiologic signs of BO were included in this analysis. The total amount of treatment cycles with pulse methylprednisolone therapy ranged from 1 to 6 cycles (median four cycles). Oxygen saturation increased significantly with normalization of oxygen saturation at the end of therapy in all individuals. Normal oxygen saturation was maintained in all but one patient during follow-up (mean follow-up period 42 {plus/minus} 20 months, range 19-67 months). Forced expiratory volume in 1 s (FEV1) was within the normal range prior BMT and significantly diminished at the time of BO diagnosis. Treatment led to stabilization of lung function, with a significant improvement of FEV1 after 2 months. In all, 7/9 patients remained in clinically stable condition without further deterioration of lung function during follow-up. These data would suggest that anti-inflammatory therapy may be a valuable treatment option in paediatric patients with bronchiolitis obliterans after BMT.

Citing Articles

Diagnosis of Post-Hematopoietic Stem Cell Transplantation Bronchiolitis Obliterans Syndrome in Children: Time for a Rethink?.

Shanthikumar S, Gower W, Cooke K, Bergeron A, Schultz K, Barochia A Transplant Cell Ther. 2024; 30(8):760-769.

PMID: 38897861 PMC: 11393806. DOI: 10.1016/j.jtct.2024.05.012.


Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.

Williams K, Pavletic S, Lee S, Martin P, Farthing D, Hakim F Transplant Cell Ther. 2022; 28(5):264.e1-264.e9.

PMID: 35114411 PMC: 9081205. DOI: 10.1016/j.jtct.2022.01.021.


Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans.

Weng T, Lin X, Wang L, Lv J, Dong L J Thorac Dis. 2021; 13(8):4775-4784.

PMID: 34527318 PMC: 8411176. DOI: 10.21037/jtd-20-3195.


Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children.

Chen X, Shu J, Huang Y, Long Z, Zhou X Exp Ther Med. 2020; 20(3):2649-2656.

PMID: 32765758 PMC: 7401899. DOI: 10.3892/etm.2020.8983.


Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation.

Seval G, Topcuoglu P, Demirer T Balkan Med J. 2018; 35(2):131-140.

PMID: 29553463 PMC: 5863250. DOI: 10.4274/balkanmedj.2017.1635.